目的:我们通过流式细胞术评估了红细胞(RBC)CD105和侧向散射(SSC)参数在检测骨髓标本中低级别骨髓增生异常肿瘤(MDS)中的实用性。
方法:通过流式细胞术回顾性评估结合CD105或SSC与Meyerson-Alayed评分系统(MASS)指标的10个RBC参数在检测低度MDS(n=56)中的实用性。
结果:单因素分析中骨髓增生异常肿瘤与7个红细胞参数相关。使用基于RBC指标和MASS参数的最佳和95%特异性水平的截止值进行多变量分析,揭示了CD105阳性和CD105阴性RBC分数的SSC比率(CD105/-SSC);RBC的CD105阳性分数的百分比和变异系数(CD105%,CD105+CV)作为显著的RBC变量出现。确定了使用这些RBC值以及MASS参数的两个简单评分方案:1使用CD105+/-SSC,CD105%,和CD105+CV与CD177阳性粒细胞的百分比(CD177%),成髓细胞百分比(CD34%),和粒细胞SSC(GranSSC),另一个结合了CD105+/-SSC,CD105+CV,CD177%,CD34%,GranSSC,和B细胞祖细胞百分比。两者都表现出大约80%的灵敏度,与细胞减少性对照相比,MDS检测的特异性约为90%。
结论:红细胞参数,CD105+/-SSC,通过流式细胞术评估低度MDS似乎是有益的。
OBJECTIVE: We assessed the utility of red blood cell (RBC) CD105 and side scatter (SSC) parameters by flow cytometry for the detection of low-grade myelodysplastic neoplasms (MDS) in bone marrow specimens.
METHODS: Ten RBC parameters incorporating CD105 or SSC combined with the Meyerson-Alayed scoring system (MASS) metrics were retrospectively evaluated by flow cytometry for utility in detecting low-grade MDS (n = 56) compared with cytopenic controls (n = 86).
RESULTS: Myelodysplastic neoplasms were associated with 7 of the RBC parameters in univariate analysis. Multivariate analysis using cutoff values based on optimal and 95% specificity levels of the RBC metrics and the MASS parameters revealed the SSC ratio of CD105-positive and CD105-negative RBC fractions (CD105+/- SSC); the percentage and coefficient of variation of the CD105-positive fraction of RBCs (CD105%, CD105+CV) emerged as significant RBC variables. Two simple scoring schemes using these RBC values along with MASS parameters were identified: 1 using CD105+/- SSC, CD105%, and CD105+CV combined with the percentage of CD177-positive granulocytes (CD177%), myeloblast percentage (CD34%), and granulocyte SSC (GranSSC), and the other incorporating CD105+/- SSC, CD105+CV, CD177%, CD34%, GranSSC, and B-cell progenitor percentage. Both demonstrated a sensitivity of approximately 80%, with a specificity of roughly 90% for the detection of MDS compared with cytopenic controls.
CONCLUSIONS: The red blood cell parameter, CD105+/- SSC, appears to be beneficial in the evaluation of low-grade MDS by flow cytometry.